Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Retinitis Pigmentosa (RP), Inherited Retinal Diseases
- Main trialPhase 2/3
- “The purpose of this clinical trial is to evaluate the effectiveness and safety of a single injection into the eye of an investigational gene therapy in participants with retinitis pigmentosa (RP).”In the company’s words, NCT07901751 on ClinicalTrials.gov
Other drugs for Retinitis Pigmentosa (RP)
- N-acetylcysteine amideNacuity Pharmaceuticals, Inc. · Phase 3
- UltevursenLaboratoires Thea · Phase 2
- OpCT-001BlueRock Therapeutics · Phase 1/2
- AAVB-081AAVantgarde Bio Srl · Phase 1/2
Coming up1
- Oct 2028Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | Oct 2028 | Study to Evaluate the Efficacy of a Single Intravitreal Injection of RTx-015 in Participants With Retinitis Pigmentosa (PERCEPT) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026